Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Pharmaceutical Preparations · Hayward, CA · filing with the SEC since 2017
Who owns Arcus Biosciences, Inc.
As filed with the SECHolders of 5% or more
2
Gilead Sciences, Inc. holds 24.7% of Common Stock, par value $0.0001, as its SCHEDULE 13D/A filed Aug 7, 2026 says.
Directors and officers
14
report now, of 26 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Gilead Sciences, Inc.
SCHEDULE 13D/A · filed Aug 7, 2026 · Common Stock, par value $0.0001 · 25.6% in Nov 5, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Jan 8, 2026 · Common Stock · 9.4% in Apr 17, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.5% in May 13, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What RCUS reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 28, 2023.
Insider tradesForm 4
44sales
0purchases
44sales on a scheduled plan
7people selling
$14.4Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 42 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Jaen Juan C. | President | 21 | $9.2M | 21 | 0 | $0 |
| Jarrett Jennifer | Chief Operating Officer | 5 | $2.2M | 5 | 0 | $0 |
| Rosen Terry J | Chief Executive Officer | 2 | $1.2M | 2 | 0 | $0 |
| Goeltz II Robert C. | Chief Financial Officer | 6 | $900,000 | 6 | 0 | $0 |
| Azoy Alexander | Chief Accounting Officer | 6 | $400,000 | 6 | 0 | $0 |
| Tang Carolyn C. | General Counsel | 2 | $300,000 | 2 | 0 | $0 |
| Markus Richard | Chief Medical Officer | 2 | $200,000 | 2 | 0 | $0 |